Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. In addition to its lead program, ZN-c5, an oral SERD for estrogen receptor positive, HER2-negative breast cancer, the Company is developing a broad pipeline of oncology candidates, targeting areas of major unmet medical need. The Company has offices in New York and San Diego.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/09/19 | $85,000,000 | Series C |
Eventide Asset Management Farallon Capital Management Matrix Capital Management Perceptive Advisors Redmile Group Surveyor Capital Viking Global Investors | undisclosed |
